Activation of Hageman factor by collagen.
Purified acid-soluble and insoluble human collagen accelerated the clotting of plateletpoor plasma in silicone-treated tubes. The clot-promoting effect did not appear to be due to thromboplastic activity since the collagen preparations did not activate factor X in the presence of factor VII and calcium. Instead, collagen appeared to accelerate clotting by activating Hageman factor (factor XII) on the basis of the following findings: collagen increased the clot-promoting activity of partially purified Hageman factor but exerted no further effect in the presence of kaolin, a known activator of Hageman factor; clot-promoting eluates were obtained from collagen exposed to normal, hemophilic, or PTC-deficient plasma but not from collagen exposed to Hageman or PTA-deficient plasma. The collagen molecule itself appeared to be required for the clot-promoting activity since digestion with collagenase or thermal denaturation at pH 2.5 (about 35 degrees C) resulted in very marked reduction in clot-promoting activity. Since thermal denaturation is associated with transformation of collagen structure from triple helical to random coil form, it is suggested that the native form of collagen is essential for the ability to activate Hageman factor. Blockage of the free amino groups by treatment with nitrous acid or dinitrofluorobenzene only slightly reduced the clot-promoting activity of collagen. In contrast, since addition of cationic proteins to collagen markedly reduced pro-coagulant activity it is suggested that negatively charged sites on the collagen molecule are critical for Hageman factor activation. This suggestion is supported by the finding that pepsin treatment of collagen, which removes the predominantly negatively charged telopeptides, results in significant decrease in coagulant activity. Esterification of collagen, which neutralizes 80-90% of the free carboxyl groups, reduced coagulant activity by over 90% and it is suggested that the free carboxyl groups of glutamic and aspartic acids provide the negatively charged sites critical for Hageman factor activation.
D000328:Adult; D001224:Aspartic Acid / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000097:blood; D001780:Blood Coagulation Tests; D001809:Blood Viscosity; D002118:Calcium / Q000494:pharmacology; D002648:Child; D003094:Collagen / Q000032:analysis / Q000494:pharmacology*; D005174:Factor XII; D005971:Glutamates / Q000494:pharmacology; D006358:Hot Temperature; D006801:Humans; D007616:Kaolin / Q000494:pharmacology; D003012:Microbial Collagenase / Q000494:pharmacology; D009578:Nitrobenzenes / Q000494:pharmacology; D010434:Pepsin A / Q000494:pharmacology; D012867:Skin / Q000032:analysis; D012965:Sodium Chloride / Q000494:pharmacology; D013925:Thromboplastin / Q000032:analysis
D005971:Glutamates; D009578:Nitrobenzenes; D007616:Kaolin; D001224:Aspartic Acid; D012965:Sodium Chloride; D005174:Factor XII; D003094:Collagen; D013925:Thromboplastin; D010434:Pepsin A; D003012:Microbial Collagenase; D002118:Calcium